Kidney Transplant Rejection Market on Track for Major Expansion by 2034, According to DelveInsight | GE Healthcare, Viela Bio, Eledon Pharma, Neovii Biotech, GlaxoSmithKline, Novartis, Medeor

Posted on
by

Kidney Transplant Rejection Market on Track for Major Expansion by 2034, According to DelveInsight | GE Healthcare, Viela Bio, Eledon Pharma, Neovii Biotech, GlaxoSmithKline, Novartis, Medeor
The Key Kidney Transplant Rejection Companies in the market include – Eledon Pharmaceuticals, Sanofi, Azurity Pharmaceuticals, Sanofi, Bristol Myers Squibb, Medeor Therapeutics, Talaris Therapeutics, CSL Behring, Eledon Pharmaceuticals, GE Healthcare, Viela Bio, Eledon Pharmaceuticals, Neovii Biotech, GlaxoSmithKline, Novartis, Hansa Biopharma AB, Astellas Pharma Inc, Sanofi, Bristol-Myers Squibb, and others.

 

DelveInsight’s “Kidney Transplant Rejection Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Kidney Transplant Rejection, historical and forecasted epidemiology as well as the Kidney Transplant Rejection market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Kidney Transplant Rejection market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Kidney Transplant Rejection Market Forecast

 

Some of the key facts of the Kidney Transplant Rejection Market Report:

  • The Kidney Transplant Rejection market size was valued ~USD 3,970 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

  • In November 2025, Eledon Pharmaceuticals’ lead candidate, tegoprubart, is advancing to late-stage trials for kidney transplant rejection prevention, despite not meeting its primary efficacy endpoint. In the Phase II BESTOW trial (NCT06126380), tegoprubart did not show significant improvements in estimated glomerular filtration rate (eGFR) compared with the standard immunosuppressant, tacrolimus. After 12 months, patients receiving the anti-CD40 ligand-binding antibody had an eGFR of 69 mL/min/1.73m², while those on tacrolimus showed an eGFR of 66 mL/min/1.73m².

  • In September 2025, The U.S. Food and Drug Administration (FDA) authorized the first clinical trials to transplant genetically modified pig kidneys into patients with kidney failure. United Therapeutics will begin with six participants suffering from end-stage renal disease and may expand to 50 patients if initial results are favorable. eGenesis plans to start with three patients, with staged expansion to follow. Eligible participants are typically 55 to 70 years old, have been on dialysis for at least six months, and are either ineligible for a human kidney transplant or unlikely to receive one within five years. The trials will include careful monitoring, a 24-week post-transplant follow-up, and lifelong patient surveillance.

  • In May 2024, Human Immunology Biosciences (HI-Bio) has announced favorable results from its Phase II clinical trial of felzartamab for treating late antibody-mediated rejection (AMR) in kidney transplant recipients. This investigator-sponsored, double-blind, placebo-controlled study was designed to assess the safety and tolerability of felzartamab in adults who experienced late AMR, at least six months after kidney transplantation.

  • The market for kidney transplant rejection prophylaxis in the US was valued at around USD 2,448 million in 2023 and is expected to grow with the introduction of new therapies.

  • The total market size for EU4 and the UK was estimated at approximately USD 1,423 million in 2023, accounting for nearly 36% of the overall market revenue for the 7MM.

  • In 2023, France was the market leader among the EU4 countries and the UK, generating approximately USD 361 million, closely followed by the UK with around USD 360 million.

  • In 2023, the market size for kidney transplant rejection prophylaxis in Japan was approximately USD 99 million, with expectations for growth during the forecast period from 2024 to 2034.

  • Estimates indicate that MDR-101 is projected to generate around USD 332.8 million by 2034 across the 7MM.

  • In 2023, approximately 44,000 new kidney transplant cases were reported across the 7MM, with numbers projected to increase by 2034.

  • DelveInsight estimates that around 27,000 kidney transplant cases occurred in the US in 2023, with the figure projected to grow by 2034.

  • In 2023, the US recorded about 2,000 acute and 8,000 chronic kidney transplant rejection cases, with these numbers anticipated to rise by 2034.

  • In 2023, the UK reported the highest number of living kidney transplants among the EU4 and the UK, with approximately 46,000 cases, followed by France with nearly 45,000. Italy had the lowest, recording around 28,000 cases.

  • In 2023, EU4 and the UK reported about 2,000 acute and 4,000 chronic kidney transplant rejection cases. By 2034, these figures are projected to rise to nearly 4,000 acute cases and 7,000 chronic cases.

  • In 2023, Japan recorded around 2,000 kidney transplant cases, with this number expected to increase by 2034, growing at a CAGR of 0.7%.

  • Key Kidney Transplant Rejection Companies: Eledon Pharmaceuticals, Sanofi, Azurity Pharmaceuticals, Sanofi, Bristol Myers Squibb, Medeor Therapeutics, Talaris Therapeutics, CSL Behring, Eledon Pharmaceuticals, GE Healthcare, Viela Bio, Eledon Pharmaceuticals, Neovii Biotech, GlaxoSmithKline, Novartis, Hansa Biopharma AB, Astellas Pharma Inc, Sanofi, Bristol-Myers Squibb, and others

  • Key Kidney Transplant Rejection Therapies: Tegoprubart (AT-1501), Riliprubart (BIVV020, SAR445088), MYHIBBIN, THYMOGLOBULIN, NULOJIX, MDR-101, MDR-102, FCR001, Clazakizumab, Tegoprubart, Sonazoid, Belatacept, AT-1501, Simulect, belimumab, CFZ533 – MMF – CS, Imlifidase, tacrolimus, BIVV020 (SAR445088), Cyclosporine, and others

  • The Kidney Transplant Rejection epidemiology based on gender analyzed that there is no gender-based difference; however, older individuals have a higher incidence of kidney transplant rejection than young individuals.

  • The Kidney Transplant Rejection market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Kidney Transplant Rejection pipeline products will significantly revolutionize the Kidney Transplant Rejection market dynamics.

 

Kidney Transplant Rejection Overview

Kidney transplant rejection occurs when the recipient’s immune system recognizes the transplanted kidney as foreign and attacks it. This immune response can damage or destroy the new kidney, impairing its function. Rejection can be acute (occurring shortly after the transplant) or chronic (developing over months or years). Symptoms may include fever, reduced urine output, swelling, or pain near the transplant site, but it can also be asymptomatic and detected through routine tests. Treatment typically involves immunosuppressive medications to prevent or manage rejection and ensure the transplanted kidney functions properly.

 

Get a Free sample for the Kidney Transplant Rejection Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/kidney-transplant-rejection-market

 

Kidney Transplant Rejection Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Kidney Transplant Rejection Epidemiology Segmentation:

The Kidney Transplant Rejection market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Kidney Transplant Rejection

  • Prevalent Cases of Kidney Transplant Rejection by severity

  • Gender-specific Prevalence of Kidney Transplant Rejection

  • Diagnosed Cases of Episodic and Chronic Kidney Transplant Rejection

 

Download the report to understand which factors are driving Kidney Transplant Rejection epidemiology trends @ Kidney Transplant Rejection Epidemiology Forecast

 

Kidney Transplant Rejection Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Kidney Transplant Rejection market or expected to get launched during the study period. The analysis covers Kidney Transplant Rejection market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Kidney Transplant Rejection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Kidney Transplant Rejection Therapies and Key Companies

  • Tegoprubart (AT-1501): Eledon Pharmaceuticals

  • Riliprubart (BIVV020, SAR445088): Sanofi

  • MYHIBBIN: Azurity Pharmaceuticals

  • THYMOGLOBULIN: Sanofi

  • NULOJIX: Bristol Myers Squibb

  • MDR-101: Medeor Therapeutics

  • MDR-102: Medeor Therapeutics

  • FCR001: Talaris Therapeutics

  • Clazakizumab: CSL Behring

  • Tegoprubart: Eledon Pharmaceuticals

  • Sonazoid: GE Healthcare

  • Belatacept: Viela Bio

  • AT-1501: Eledon Pharmaceuticals

  • Simulect: Neovii Biotech

  • belimumab: GlaxoSmithKline

  • CFZ533 – MMF – CS: Novartis

  • Imlifidase: Hansa Biopharma AB

  • tacrolimus: Astellas Pharma Inc

  • BIVV020 (SAR445088): Sanofi

  • Cyclosporine: Bristol-Myers Squibb

 

Discover more about therapies set to grab major Kidney Transplant Rejection market share @ Kidney Transplant Rejection Treatment Landscape

 

Scope of the Kidney Transplant Rejection Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Kidney Transplant Rejection Companies: Medeor Therapeutics, Talaris Therapeutics, CSL Behring, Eledon Pharmaceuticals, GE Healthcare, Viela Bio, Eledon Pharmaceuticals, Neovii Biotech, GlaxoSmithKline, Novartis, Hansa Biopharma AB, Astellas Pharma Inc, Sanofi, Bristol-Myers Squibb, and others

  • Key Kidney Transplant Rejection Therapies: Eledon Pharmaceuticals, Sanofi, Azurity Pharmaceuticalsm, Sanofi, Bristol Myers Squibb, Tegoprubart (AT-1501), Riliprubart (BIVV020, SAR445088), MYHIBBIN, THYMOGLOBULIN, NULOJIX, MDR-101, MDR-102, FCR001, Clazakizumab, Tegoprubart, Sonazoid, Belatacept, AT-1501, Simulect, belimumab, CFZ533 – MMF – CS, Imlifidase, tacrolimus, BIVV020 (SAR445088), Cyclosporine, and others

  • Kidney Transplant Rejection Therapeutic Assessment: Kidney Transplant Rejection current marketed and Kidney Transplant Rejection emerging therapies

  • Kidney Transplant Rejection Market Dynamics: Kidney Transplant Rejection market drivers and Kidney Transplant Rejection market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Kidney Transplant Rejection Unmet Needs, KOL’s views, Analyst’s views, Kidney Transplant Rejection Market Access and Reimbursement

 

To know more about Kidney Transplant Rejection companies working in the treatment market, visit @ Kidney Transplant Rejection Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Kidney Transplant Rejection Market Report Introduction

2. Executive Summary for Kidney Transplant Rejection

3. SWOT analysis of Kidney Transplant Rejection

4. Kidney Transplant Rejection Patient Share (%) Overview at a Glance

5. Kidney Transplant Rejection Market Overview at a Glance

6. Kidney Transplant Rejection Disease Background and Overview

7. Kidney Transplant Rejection Epidemiology and Patient Population

8. Country-Specific Patient Population of Kidney Transplant Rejection

9. Kidney Transplant Rejection Current Treatment and Medical Practices

10. Kidney Transplant Rejection Unmet Needs

11. Kidney Transplant Rejection Emerging Therapies

12. Kidney Transplant Rejection Market Outlook

13. Country-Wise Kidney Transplant Rejection Market Analysis (2020–2034)

14. Kidney Transplant Rejection Market Access and Reimbursement of Therapies

15. Kidney Transplant Rejection Market Drivers

16. Kidney Transplant Rejection Market Barriers

17. Kidney Transplant Rejection Appendix

18. Kidney Transplant Rejection Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/